- Amgen's (AMGN) Vectibix meets its primary endpoint of non-inferiority (overall survival) to Erbitux (BMY, LLY, MKGAF.PK) in a Phase 3 trial in patients with wild-type KRAS metastatic colorectal cancer that has not responded to chemotherapy.
- Median OS for Vectibix was 10.4 months compared to 10 months for Erbitux.
- Median PFS for Vectibix was 4.1 months versus 4.4 months for Erbitux. (PR)
Amgen's Vectibix meets non-inferiority OS primary endpoint in Phase 3 study
Sep 28 2013, 22:20 ET